All In Biotech

Drug Trial Radar · NCT01287741

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Last checked: Nov 20, 2026Latest source record: Apr 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,418 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,418

Actual

Start

Jul 26, 2011

Primary completion

Apr 29, 2016

Study completion Jan 31, 2018

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Fondazione Italiana Linfomi - ETS
First posted
Feb 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m\^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • RituximabDrug

    Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.

  • ObinutuzumabDrug

    Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.

  • CyclophosphamideDrug

    Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.

  • DoxorubicinDrug

    Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.

  • VincristineDrug

    Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.

  • PrednisoneDrug

    Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Time to Progression-Free Survival (PFS), Investigator-AssessedTime frame: Baseline up to approximately 6.5 years (up to 31 January 2018)

Locations

235 sites in 29 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Ironwood Cancer TX & Rsch Ctrs

    Chandler, Arizona

  • Arizona Oncology

    Tucson, Arizona

  • California Cancer Associates for Research & Excellence, Inc.

    Encinitas, California

  • cCare

    Encinitas, California

  • UCLA - School of Medicine; Division of Hematology/Oncology

    Los Angeles, California

  • Rocky Mountain Cancer Center - Aurora

    Aurora, Colorado

  • Florida Cancer Specialists; Department of Oncology

    Fort Myers, Florida

  • Florida Cancer Specialists; Saint Petersburg

    St. Petersburg, Florida

  • Central Georgia Cancer Care PC

    Macon, Georgia

  • Illinois Cancer Care, P.C. - Galesburg

    Galesburg, Illinois

  • Joliet Oncology-Hematology; Associates, Ltd.

    Joliet, Illinois

  • Cancer Care & Hematology; Specialists of Chicagoland

    Niles, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • Mercy Oncology / Hematology Center; Oncology

    Portland, Maine

  • Park Nicollet Clin-Cancer Ctr

    Saint Louis Park, Minnesota

  • Minnesota Oncology Hematology Woodbury

    Woodbury, Minnesota

  • New York Oncology Hematology, P.C.

    Albany, New York

  • Mecklenburg Medical Group Charlotte

    Charlotte, North Carolina

  • Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates

    Winston-Salem, North Carolina

  • Signal Point Clinical; Research Center, LLC

    Middletown, Ohio

  • Cleveland CL N Coast Cancer Cr

    Sandusky, Ohio

  • Willamette Valley Cancer Insitute and Research Center

    Springfield, Oregon

  • Medical University of SC (MUSC)

    Charleston, South Carolina

  • South Carolina Oncology Associates - SCRI

    Columbia, South Carolina

  • Chattanooga Oncology and Hematology Associates, PC

    Chattanooga, Tennessee

  • Tennessee Onc., PLLC - SCRI

    Nashville, Tennessee

  • Texas Oncology, Pa - Amarillo

    Amarillo, Texas

  • Texas Oncology-Fort Worth 12th Ave

    Fort Worth, Texas

  • MD Anderson Cancer Center Department of Lymphoma & Myeloma

    Houston, Texas

  • Cancer Care Centers of South Texas-HOAST - San Antonio

    New Braunfels, Texas

  • Virginia Cancer Institute

    Richmond, Virginia

  • Blue Ridge Cancer Care

    Roanoke, Virginia

  • Virginia Cancer Specialists - Winchester

    Winchester, Virginia

  • Northwest Medical Specialties

    Tacoma, Washington

  • Wenatchee Valley Hospital & Clinics

    Wenatchee, Washington

  • Instituto Damic

    Córdoba, Argentina

  • Sanatorio Britanico: Hematologia

    Rosario, Argentina

  • Sanatorio Parque de Rosario

    Rosario, Argentina

  • Cairns Base Hospital; Cancer Care Centre

    Cairns, Queensland, Australia

Showing 40 of 235 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.